key: cord-1020677-bqob0o7t
authors: Bazan, Hernan A.; Bhattacharjee, Surjyadipta; Burgos, Carolina; Recio, Javier; Abet, Valentina; Pahng, Amanda R.; Jun, Bokkyoo; Heap, Jessica; Ledet, Alexander J.; Gordon, William C.; Edwards, Scott; Paul, Dennis; Alvarez-Builla, Julio; Bazan, Nicolas G.
title: A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis
date: 2020-06-30
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2020.112600
sha: 8efc92d06bc6c80ef150457aa584a00bc7c88fe9
doc_id: 1020677
cord_uid: bqob0o7t

Although acetaminophen (ApAP) is one of the most commonly used medicines worldwide, hepatotoxicity is a risk with overdose or in patients with compromised liver function. ApAP overdose is the most common cause of acute fulminant hepatic failure. Oxidation of ApAP to N-acetyl-p-benzoquinone imine (NAPQI) is the mechanism for hepatotoxicity. 1 is a non-hepatotoxic, metabolically unstable lipophilic ApAP analog that is not antipyretic. The newly synthesized 3 is a non-hepatotoxic ApAP analog that is stable, lipophilic, and retains analgesia and antipyresis. Intraperitoneal or po administration of the new chemical entities (NCEs), 3b and 3r, in concentrations equal to a toxic dose of ApAP did not result in the formation of NAPQI. Unlike livers from NCE-treated mice, the livers from ApAP-treated mice demonstrated large amounts of nitrotyrosine, a marker of mitochondrial free radical formation, and loss of hepatic tight junction integrity. Given the widespread use of ApAP, hepatotoxicity risk with overuse, and the ongoing opioid epidemic, these NCEs represent a novel, non-narcotic therapeutic pipeline.

Management of acute and chronic pain is one of the most prevalent and costly public 16 health issues worldwide. In the U.S. alone, pain affects more adults than diabetes and cancer 17 combined(1) with an estimated cost of $635 billion to the healthcare system each year(2). Current 18 analgesics have the potential risk for abuse (e.g., opioids), liver damage (acetaminophen; ApAP), 19 or kidney injury (non-steroidal anti-inflammatory drugs; NSAIDs). A widespread dependence on 20 opioids, particularly following work-related accidents, and high rates of overdose in the U.S. 21 further underscore the need for safer, effective, non-opioid pain medications. In addition to 22 NSAIDs, N-Acetyl-4-aminophenol (acetaminophen, paracetamol, ApAP)( Fig. S1 ) is the most 23 frequently used over-the-counter (OTC) analgesic and antipyretic drug(3). Interestingly, the 24 utility of ApAP and NSAIDs over opioids for moderate/severe pain was demonstrated recently in 25 a trial of 416 randomized patients with moderate/severe acute extremity pain; no difference in 26 pain reduction was found at 2 hours following a single-dose NSAID and ApAP compared to an 27 opioid/ApAP analgesic combination(4). 28 Although ApAP has been used for several decades, its precise mechanism of action 29 (MOA) remains unidentified(5, 6). However, increasing evidence indicates that N-30 arachidonoylaminophenol (AM404) may be fundamental to ApAP's analgesic effects. In the 31 liver, ApAP is converted to p-aminophenol, which in turn is converted by fatty acid amide 32 hydrolase (FAAH) in the brain in the presence of arachidonic acid to make AM404 (Fig. S1)(7, 33 8). In the brain, AM404 may exert analgesia via the endogenous cannabinoid system through 34 CB 1 receptors (7, 9) and activation of the transient receptor potential vanilloid-1 (TRPV1) 35 channel-receptor signaling in the periaqueductal gray area(7). Remarkably, the FAAH/CB 1 36 receptor/TRPV1 channel triad thought necessary for ApAP analgesia co-locates in this area of the 37 brain (7, 10) . Beyond this, the central mechanisms for ApAP's analgesia are still unknown. 38 However, ApAP has a narrow therapeutic index, and hepatotoxicity is a significant risk 39 that comes with deliberate (e.g., suicide attempt) or unintentional overuse or use in patients with 40 compromised liver function. In fact, every year around 30,000 patients in the U.S. are hospitalized 41 due to ApAP hepatotoxicity(11). ApAP hepatotoxicity is linked to the formation of the 42 electrophilic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), through an oxidative process 43 mediated by cytochrome P450 (CYP450), mainly by the CYP2E1 and CYP3A4 isoforms. 44 Normally, NAPQI is neutralized by a Phase II conjugative process, mediated by glutathione 45 (GSH)(12), and eliminated as a mercapturic acid (Fig. S2 , Path A). In overdoses, the conjugative 46 Phase II mechanism becomes saturated, resulting in the depletion of GSH stock and a NAPQI 47 reaction using nucleophilic macromolecules; this triggers a cascade of events that results in 48 hepatocellular death (Fig. S2 , Path B) (13, 14) . 49 Because of ApAP's narrow therapeutic index and the clinical demand for safer novel non-50 opioid analgesics, we undertook a research effort to find ApAP analogs that lacked 51 hepatotoxicity. We created more lipophilic derivatives with the insertion of a 1,1-dioxo-1,2-52 benzothiazol-3-one moiety (hereafter referred to as "imide") onto the methyl group of ApAP(15). 53 Unexpectedly, the resulting compound 1 (Scheme 1) maintained the in vivo analgesic profile of 54 ApAP, while hepatotoxicity was considerably decreased; however, 1 is quickly metabolized in 55 vivo into the main metabolite 2. The main metabolite 2 is a comparatively hydrosoluble 56 carboxylic acid facilitating its quick excretion by urine. To modulate the pharmacokinetic profile 57 of 1, a new series of analgesics is now described. These compounds are obtained by the ring 58 opening of the imide moiety in 1 to yield the corresponding N-substituted amides 3(16). The 59 synthesis and characterization of the novel class of analogs depicted in 3 are described to identify 60 new chemical entities that lack hepatotoxicity and maintain analgesic and antipyretic properties. 61 Compared to 2, the novel 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analogs 62 exhibit increased stability, elevated lipophilicity, and slowed hydrolysis of the amide group. 90 We first screened the library of compounds in PHH (Fig. 1) , and the compounds that 91 consistently proved to have toxicity similar to or worse than ApAP were discarded. A pattern of 92 cell protection was evident; compounds that caused a decrease in hepatic cell death (as measured 93 by low LDH release) also caused an increase in production of GSH. Decreased toxicity was noted 94 for 3b and 3r in comparison to ApAP: LDH release was consistently decreased, and the amount 95 of reduced GSH was consistently increased for 3b and 3r, whereas ApAP led to increased LDH 96 release and depletion of the cytoprotective GSH in a time and dose-dependent manner. The 97 compounds that proved to be hepatotoxic with the initial screening on PHH were not assayed in 98 HepaRGs (Fig. 2) . In this transformed hepatic cell line, a dose and time-dependent effect of lack 99 of hepatotoxicity was also observed for 3b and 3r but not for ApAP, leading us to focus on these 100 two lead compounds for further in vivo toxicity assays, followed by analgesia and antipyretic 101 models.

102 Fig. 1 . Hepatotoxicity profile of ApAP and novel compounds 3 in primary human hepatocytes (PHH). LDH release was measured at 3 h, 6 h, and 12 h after exposure of PHH to either (A) 500 µM or (B) 1,000 µM of drugs, respectively. Similarly, levels of reduced GSH were measured at 3 h, 6 h, and 12 h after exposure of PHH to (C) 500 µM or (D) 1,000 µM of drugs. For the measurement of LDH assay (A and B), Control is LDH-positive control, i.e., solution, which will lyse the plasma membrane and release the maximum amount of LDH into the cell culture medium for the specific cell type in which the cytotoxicity is measured (PHH in this case). For the measurement of GSH assay (C and D), Control is vehicle (1x PBS), which when added to the cells should show the normal level of GSH for the specific cell type in which the cytotoxicity is measured (PHH in this case). (2-column fitting image)

Hepatotoxicity profile of ApAP and select novel compounds 3 in HepaRGs. Hepatotoxicity profiles were assayed in the human transformed hepatic cell line, HepaRG, at increasing time points and concentrations. LDH release after incubation with various compounds at 50, 100, 1000 and 5000 µM was measured at time points of 6 h, 12 h, and 24 h, as shown in (A), (B), and (C), respectively. Note that the compounds that proved to be hepatotoxic with the initial screening in PHH were not assayed in HepaRGs. Similarly, levels of reduced GSH were measured at 6 h, 12 h, and 24 h, as shown respectively in (D), (E), and (F), after exposure of various compounds in HepaRG cells under 50, 100, 1000 and 5000 µM of compound. Results from this initial screening led us to choose 3b and 3r for further characterization using in vivo toxicity assays, followed by analgesia and antipyretic models. (2-column fitting image) 104 Fig. 3 . In vivo liver function tests (LFTs) and serum creatinine. The liver function assays, (A) alanine aminotransferase, (B) aspartate aminotransferase, and (C) alkaline phosphatase, were carried out with select novel compounds and ApAP, as well as (D) serum creatinine to assess the effects on renal function. Protein levels were measured in serum collected via transcardial perfusion from mice dosed at 600 mg/kg of either ApAP or select novel compounds; n = 5 mice per compound were dosed, and serum was collected. (*p < 0.0001; #p < .01). For all novel compounds screened, measurements of ALT, AST, ALP and serum creatinine levels were comparable to control, i.e., vehicle-injected mice (0.9% NaCl), while the levels for ApAP-injected mice were significantly high. (2-column fitting image) Next, a marked reduction in LFTs was noted for 3b and 3r when compared to ApAP in an 106 in vivo model (Fig. 3) . Increased levels of ALT, aspartate transaminase (AST), and alkaline 107 phosphatase (ALP) were noted in ApAP-treated mice but not in mice treated with equivalent toxic 108 doses (600 mg/kg) of 3b and 3r. Likewise, the effect on renal function was then assessed with 109 large doses of ApAP and the novel compounds, and unlike 3b and 3r, serum creatinine was 110 moderately elevated with 600 mg/kg of ApAP (p < .01 Next, we asked whether the reason for the lack of hepatotoxicity was due to a decrease or 118 lack of formation of the toxic quinonimine 8 (NAPQI) by the leading compound 3 compared to 119 ApAP ( Fig. 5.) . ApAP-induced hepatotoxicity is related to the formation of the electrophilic 120 reactive metabolite, NAPQI, by CYP2E1 and CYP3A4, which is detoxified through conjugation 121 with GSH ( Fig. S2) . GSH is an important cellular antioxidant in the liver and GSH depletion is 122 likely an important event in ApAP-induced acute liver injury (AILI), although this mechanism is 123 still poorly understood (20) . Following toxic ApAP doses, GSH depletion is followed by Samples from ApAP-injected animals (ip) with a standard NAPQI spiked on the sample, demonstrating the same retention time in the chromatogram. (C) Histograms demonstrate that NAPQI is significantly enhanced only after injection of ApAP, regardless of administration route. (D) Administration of the drug via po injection resulted in a mild increase in serum NAPQI; however, this increase is markedly less than the increase after ApAP is injected via the same administration route. (E) The mass spectrum shows the full fragmentation pattern of the NAPQI standard. The molecular structure inside of the spectrum suggests the possible fragments of NAPQI molecules (m/z transition 150.3/108.1) to produce given mass spectrum. (F) NAPQI full fragmentation spectrum obtained from the serum of a mouse that was ApAP injected (ip) shows very good matches to the NAPQI standard, suggesting that the conversion of NAPQI from ApAP was successfully done and able to be measured in the serum. (2-column fitting image) and internal standard responded best to positive ionization with the protonated ions [M + H] + 134 presenting as major peaks in the fragmentation pattern of mass spectrum for NAPQI (Fig. 6E) . 135 The product ion mass spectrum obtained in multiple reaction monitoring (MRM) mode was used 136 to identify NAPQI by monitoring the m/z transition 150.3 → 108.1.

Histological evidence for the lack of hepatotoxicity Hematoxylin and Eosin (H&E)-stained liver sections from CD1 mice after toxic doses 139 (600 mg/kg) of ApAP demonstrate centrilobular hepatic hemorrhagic necrosis, but a healthy liver 140 architecture was maintained with 3b and 3r (Fig. 7) . 141 Staining for nitrotyrosine, a marker of mitochondrial free radical formation and hepatocyte 142 injury, correlated with the centrilobular necrosis noted on the H&E stains. Loss of hepatic tight 143 junctions, which has been recently implicated as a topographical mechanism in ApAP-induced 144 hepatotoxicity(23), was noted in ApAP-treated mice with loss of 'chicken wire' hepatic tight 145 junctions, but this was preserved with 3b and 3r. A large number of apoptotic nuclei were noted 146 in ApAP-treated animals but not in 3b and 3r. Lastly, Kaplan-Meier survival curves were 147 generated using four groups (n=20 per group) of male CD1 mice exposed to 600 mg/kg po of 148 Fig. 7 . Lack of hepatotoxicity of compounds 3b and 3r. (A) Hematoxylin and Eosin-stained liver sections (100x). Centrilobular hepatic hemorrhagic necrosis is evident after exposure of male CD1 mice to toxic doses (600 mg/kg) ApAP via po injection, but not compounds 3b or 3r. Note that a healthy liver architecture if maintained with compounds 3b and 3r. (B) Nitrotyrosine-labeled hepatic sections (100x). (C) (Zonula Occludens-1 (ZO-1) staining demonstrating the loss of "chicken wire" hepatic tight junctions, which exist between hepatocytes. Flat, 2-dimensional hepatocyte cultures show clear "chicken wire" tight junction labeling with ZO-1, a constituent protein. ZO-1 labeled sections of vehicle (0.9% NaCl) control, ApAP, 3b, and 3r (all 200x) show good ZO-1 label (brown bands, white arrows); however, the ZO-1 bands tend to run out of the section plane (these are liver sections). Note the very dark ZO-1 labeling around the small associate blood vessels. (D) 3-dimensional stacking of Zo-1 staining (1000x) for sections from vehicle (0.9% NaCl) control, ApAP, 3b, and 3r. (E) Cell death was observed in ApAP-treated mice, unlike in the vehicle (0.9% NaCl) treated controls or in the 3b-or 3r-treated mice, as assessed by TUNEL-positive nuclear staining for apoptosis (all 200x). (2column fitting image) either ApAP, 3b, 3r, or 0.9% NaCl (Vehicle) (Fig. 8) Next, we sought to determine whether 3b and 3r have comparable analgesic and antipyretic properties to ApAP. Analgesia was assessed utilizing the visceral pain acetic acid-induced abdominal writhing assay(24) in CD1 male mice. Abdominal contraction (writhing) is induced in mice by an ip injection of 0.4% acetic acid at a dose of 10 mL/kg, 25 min after drug administration at concentrations of 0-80 mg/kg ( Fig. 9A -C; associated scatter plots (Fig 8D-F) ). and 14.7 μmol/kg, respectively (Fig. 9A) . Analgesia was further assessed using the von Frey assay hyperalgesia model ( Fig. 11 ) in male Sprague Dawley rats for ApAP, 3b, and 3r. In this 160 Fig. 9 . Analgesia and antipyretic assays. The Abdominal Acetic Acid Writhing Assay counts the number of writhes for a period of 10 minutes 30 minutes after administration of (A) ApAP, (B) 3b, and (C) 3r with corresponding scatter plots of individual animals for (D) ApAP, (E) 3b and (F) 3r. Each drug was tested for analgesia using this assay at doses 5, 10, 20, 40, and 80 mg/kg respectively and dose response curves were generated and ED 50 values for ApAP, 3b, and 3r calculated from them as shown in (Fig. 9A) . The decrease in the number of writhes by a drug were compared to the number of writhes in mice injected with vehicle (0.9% NaCl) and analyzed for statistical significance with a one-way ANOVA followed Sidak's multiple comparisons post-hoc test. p < 0.05 was considered as statistically significant. (G) Summary of Baker's yeast-induced pyresis. The number of animals per group, n = 10. Baseline temperatures for each mouse was recorded, and then baker's yeast (pyrogen) was injected to each mouse. 4 hours after yeast administration there was comparable fever development in all groups. ApAP effectively reduced fever, as did compounds 3b and 3r at 2 h after drug injection (6-h time point). The decrease in temperature at 2 h after drug administration, were compared to the elevated temperature at 4 h after yeast injection (fever) and analyzed for statistical significance with a one-way ANOVA followed Sidak's multiple comparisons post-hoc test. p < 0.05 was considered as statistically significant. Latencies for the withdrawal of the right hind foot (un-injected control) of 0.9% NaCl (vehicle) injected animals. Changes of the withdrawal thresholds or latencies induced by a drug were analyzed for statistical significance with a one-way ANOVA followed Sidak's multiple comparisons posthoc test. For ApAP, 4 doses at 10, 32, 100 and 320 mg/kg respectively were tested. These doses were selected, as they were each ½ log dose higher than the previous one, so as to facilitate generating a complete dose response curve and ED 50 values were calculated. For 3b and 3r, 32 and 100 mg/kg doses were selected and ED 50 values were calculated from them data shown in (Fig. 10B) .

(2-column fitting image) 

(3a) 192 Compound 1 (0. 332 g, 1 mmol) was added to an ammonium hydroxide aqueous solution (28-30% wt., 3.3 mL). 206 Compound 222 Compound 1 (0.332 g, 1 mmol) in acetonitrile (3 mL 253 Compound 1 (0.332 g, 1 mmol) was added to a solution of n-254 butylamine (0.146 g, 0.20 mL, 2 mmol) in acetonitrile (5 mL 270 Compound 285 Compound 

301 benzamide (3h) 302 Compound 1 (0.332 g, 1 mmol) was added to a solution of 1,3-303 diamino-2-propanol (0.180 g, 2 mmol) in ethanol (5 mL 316 Compound 1 (0.332 g, 1 mmol) was added to a solution of 317 cyclopentylamine (0.170 g, 0.20 mL, 2 mmol) in acetonitrile (2.5 mL 332 Compound 1 (0.332 g, 1 mmol) was added to a mixture of 333 benzylamine (0.214 g, 0.22 mL, 2 mmol) in water (5 mL 

348 (3k) 349 Compound 1 (0.332 g, 1 mmol) was added to a mixture of 4- 20.7, 42.4, 46.0, 115.0, 120.9, 127.3, 128.7, 361 128.8, 129.4, 130.0, 130.1, 132.8, 135.5, 135.8, 135.9, 136.9, 153.5, 165.3, 168. 

365 methylbenzamide (3l) 366 Compound 1 (0.332 g, 1 mmol) was added to a mixture of 367 4-methoxybenzylamine (0.274 g, 0.26 mL, 6 mmol) in acetonitrile (5 mL 9, 45.4, 114.6, 120.6, 123.0, 127.9, 128.3, 128.9, 129.5, 129.9, 132.4, 396 134.4, 136.5, 146.1, 146.5, 153.1, 164.9, 168.2 

401 benzamide (3n) 402 Compound 45.9, 114.9, 120.8, 125.8, 126.7, 127.0, 128.5, 129.2, 129.8, 129.9, 130.0, 414 132.7, 132.9, 135.1, 136.8, 141.2, 153.3, 165.0, 168.3 

419 benzamide (3o) 420 Compound 

(2-pyridylmethyl)benzamide (3p) 438 Compound 1 (0.332 g, 1 mmol) was added to a mixture of 2-439 picolylamine (0.216 g, 0.21 mL, 2 mmol) in acetonitrile (2.5 440 mL). The mixture was stirred for 2 h at room temperature. 2, 123.3, 123.7, 130.2, 130.3, 130.5, 131.0, 133.9, 136.9, 138.3, 138.8, 149.3, 155.4, 158.3, 451 168 

472 benzamide (3r) 473 Dopamine hydrochloride (0.379 g, 2 mmol), Na 2 CO 3 (0.212 g, 2, 120.9, 128.5, 129.1, 129.8, 129.9, 130.0, 132.6, 135.6, 136.7, 143.4, 145.0, 153.3, 165. 

490 (3s) 491 Compound 1 (0.332 g, 1 mmol) was added to a solution of 6, 55.4, 116.1, 123.3, 129.9, 130.4, 130.5, 130.9, 134.0, 137.5, 138.4, 155.7, 169.2, 170.7; 502 Anal 

506 (3t) 507 Compound 1 (0.332 g, 1 mmol) was added to a solution of 508 morpholine (0.164 g, 0.16 mL, 2 mmol) in water (2.5 mL). 5, 46.9, 67.0, 67.1, 116.0, 123.4, 128.9, 130.3, 130.7, 131.00, 134.4, 135.7, 517 138.4, 155.5, 168.5, 170.4 

522 acetamida (3u) 523 Compound 9, 46.9, 53.1, 53.2, 63.7, 115.9, 123.3, 128.3, 128.7, 129.2, 534 130.2, 130.4, 130.4, 130.8, 134.2, 135.8, 138.2, 138.3, 155.4, 168.4, 170. within each histogram ( Fig. 9A-C) . for the rat to withdraw the stimulated paw. A brisk withdrawal of the paw (often followed by a 650 sustained retraction and/or licking) was considered a positive response, but paw withdrawals due 651 to locomotion or weight shifting were not counted. In these studies, the average baseline 652 withdrawal threshold to the electric von Frey filament (eVF) was approximately 40 g 653 pressure. After injection of CFA, the withdrawal threshold was between 20-25 g for the injected 654 left hind paw (indicating hyperalgesia/allodynia), while for un-injected right hind paw, the 655 withdrawal threshold was approximately 40 g pressure. 656 The antipyretic effect of the compounds was assessed utilizing baker yeast-induced 668 hyperthermia (15% yeast, 0.1mL/kg). All animals used in this assay were male CD1 mice, which 669 were fasted overnight (15h) before the start of the assay. The baseline temperature of all animals 

Changes of the withdrawal thresholds or latencies induced by a drug were first analyzed 690 with a one-way ANOVA. Comparisons between the effects of different drugs were then subjected to t-test for unpaired means. A value of p < 0.05 was considered significant. All statistical 692 analyses were performed using GraphPad Prism 8.3.1. 693

depletion is followed by formation of reactive oxygen and nitrogen species leading to 720 mitochondrial permeability and hepatocyte death(21). We developed a method to detect NAPQI 721 from plasma using LC-MS/MS in CD1 mice treated with ApAP, 3b or 3r (each at 600 mg/kg; 722 Fig. 6 ). Our results support the idea that they are not hepatotoxic because they do not generate 723 NAPQI(28, 29) . Moreover, (H&E)-stained liver sections from CD1 mice after a toxic (600 724 mg/kg) dose of ApAP demonstrate centrilobular hepatic hemorrhagic necrosis. In contrast, a 725 healthy liver architecture was observed in mice treated with the same dose of 3b and 3r (Fig. 7) . 

ApAP was administered in a cumulative 658 dose-response manner; injections at concentrations of 10 mg/kg, 32 mg/kg, 100 mg

Both 3b and 3r were also administered in a 660 cumulative dose-response manner; injections at concentrations of 32 mg/kg and 100 mg/kg were 661 given at intervals of 45 minutes. In all animals, eVF withdrawal threshold recordings were taken 662 at 30 minutes after drug injection in both hind paws

As 698 depicted in the graphical abstract, the N-acetyl-p-aminophenol portion of the molecule is the 699 likely analgesic fragment, which toxicity is likely reduced by the benzenesulfonamide 700 fragment. Lastly, varying the R modulates the lipophilicity and toxicity. The lack of 701 hepatotoxicity is explained by the inability of these compounds to generate 8 (N-acyl-p-702 benzoquinone imine) and the maintenance of hepatic tight junctions

Fig. 2) and in vivo (Fig. 3)

An in vivo model of visceral pain (Fig. 9A-F, Fig. 10A) and hyperalgesia/allodynia model

11) demonstrate the analgesic properties of 3b and 3r. First, we utilized the acetic acid-706 induced abdominal writhing model of visceral pain quantifies contraction of the abdominal 707 muscles and stretching of the hind limbs in response to ip injection of acetic acid

In the second model, CFA inflammatory pain assay with von Frey detection(26) the

CFA-inflamed hind paw is stimulated with a von Frey filament until the animal retracts the paw 710 from the noxious source, while the un-injected hind paw serves as a within-subject control (non-711 injured) baseline. Demonstration of efficacy in this model is valuable since

One of the mechanisms for ApAP-715 induced hepatotoxicity is via formation of the electrophilic reactive metabolite, NAPQI, which is 716 detoxified through conjugation with reduced GSH. GSH is an important cellular antioxidant in the 717 liver, and GSH depletion appears to be a key event in ApAP-induced acute liver injury, although 718 this mechanism is still poorly understood(20). However, following a toxic dose of ApAP, GSH (www.cdc.gov/opioids/strategy.html) with management of pain being the cause of long-term 736 abuse in up to half of opioid deaths. Workplace injuries may be driving many of these cases, and 737 there is evidence that prescribed oral narcotics are the most likely source of overdose (CDC 738 2016). A recent randomized clinical trial of 240 patients with chronic back pain and hip and knee 739 osteoarthritis pain showed equivalent analgesia with non-opioid medications compared to opioid 740 use(30). Additionally, use of opioids was demonstrated in a recent randomized trial of 416 741 patients to be no better than non-opioids in managing acute upper or lower extremity pain in the 742 emergency department(4). A safer, novel

We gratefully acknowledge FEDER funds and Comunidad de Madrid (CAM, project 751 B2017/BMD-3688 MULTI-TARGET&VIEW-CM FEDER FUNDS)

Instituto de Salud Carlos III (FEDER 753 funds, ISCIII RETIC REDINREN RD16/0009/0015 FEDER FUNDS) and Universidad de Alcalá 754 (CCG2017/EXP-021 and CCG2018/EXP-051) for financial support

We thank Mr. Jeremy E. Mix for their assistance 756 with animal care and analgesia assays

JAB wrote the paper and all co-authors 761 contributed to the final version. JAB, CB and VA, performed the medicinal chemistry. WCG 762 performed all histology and immunohistochemistry. SB, AP, SE, JH and DP conducted the 763 experiments for analgesia

Health Sciences Center describing the synthesis and characterization of the novel non-hepatotoxic 770 acetaminophen analogs. It is patent PCT/US2018/022029, international filing data 12.03

Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, 785 and Research

The Economic Costs of Pain in the United States. The journal of pain : 787 official journal of the

Exploring Chemical Routes Relevant to the Toxicity of 789

Paracetamol and Its meta-Analogue at a Molecular Level

Effect of a Single Dose of Oral 792

Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: 793 A Randomized Clinical Trial

How does acetaminophen work? Researchers still aren't sure

Acetaminophen from liver to 798 brain: New insights into drug pharmacological action and toxicity

Paracetamol is a centrally acting analgesic using mechanisms located 801 in the periaqueductal grey

Conversion of acetaminophen to the bioactive N-acylphenolamine 803 AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the 804 nervous system

Acetaminophen Relieves Inflammatory Pain through CB1

Cannabinoid Receptors in the Rostral Ventromedial Medulla

Hot flash: TRPV channels in the brain

A perspective on the epidemiology 811 of acetaminophen exposure and toxicity in the United States

Understanding Idiosyncratic Toxicity: Lessons Learned from 814 Drug-Induced Liver Injury

New problems arising from old drugs: second-818 generation effects of acetaminophen

Synthesis and in vivo evaluation of non-hepatotoxic acetaminophen 820 analogs

Selective Monoacetylation of Unsymmetrical Diols Catalyzed by Silica 823

Gel-Supported Sodium Hydrogen Sulfate

A highly selective and efficient acetylation of alcohols and amines with 826 acetic anhydride using NaHSO4·SiO2 as a heterogeneous catalyst using NaHSO4.SiO2 as 827 a heterogenous catalyst

First Multi-gram Preparation SCP-123, A 829 Novel Water Soluble Analgesic

Role of 831 cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during 832 acetaminophen toxicity

Acetaminophen-induced 834 hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and 835 mitochondrial permeability transition

A reliable LC-MS/MS method for the quantification of N-acetyl-p-837 benzoquinoneimine, acetaminophen glutathione and acetaminophen glucuronide in mouse 838 plasma, liver and kidney: Method validation and application to a pharmacokinetic study

Low-dose acetaminophen induces early disruption of cell-cell tight 841 junctions in human hepatic cells and mouse liver

Antagonism of the frequency of phenylquinone-induced 843 writhing in the mouse by weak analgesics and nonanalgesics

Analgesic and Anti-Inflammatory Properties of Gelsolin in Acetic Acid 846 Induced Writhing, Tail Immersion and Carrageenan Induced Paw Edema in Mice

Development of mechanical hypersensitivity in rats during heroin and 849 ethanol dependence: alleviation by CRF(1) receptor antagonism

Quantitative 852 assessment of tactile allodynia in the rat paw

Acetaminophen/paracetamol: A history of errors, failures 854 and false decisions

cytochrome P-450-mediated oxidation product of acetaminophen

Effect of Opioid vs Nonopioid Medications on Pain-Related Function in 859

Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE 860

1. We describe a novel class of diethylaminocarbonyl-2-benzenesulfamide analogs to acetaminophen/paracetamol 2. Compounds, 3b and 3r, lack the hepatotoxicity present in acetaminophen/paracetamol 3. 3b and 3r maintain analgesia and antipyresis in in vivo models

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:HAB, CBG, DP, JAB and NGB are named on a patent lodged by the Louisiana State University Health Sciences Center describing the synthesis and characterization of the novel non-hepatotoxic acetaminophen analogs. It is patent PCT/US2018/022029; international filing date: 12.03.2018; publication date: 28.02.2019. HAB and NGB are co-founders of South Rampart Pharma, LLC -a company that develops novel analgesic therapies.